Literature DB >> 7852218

Clinical application of recombinant erythropoietin in anemic cancer patients.

D H Henry1.   

Abstract

Anemia is common in cancer patients and may require treatment for symptomatic palliation. Transfusion has been the mainstay of therapy, but is not without risk. Because erythropoietin levels in cancer-related anemia are inadequate for the degree of anemia, recombinant human erythropoietin has been studied to treat the anemia. Results from these studies are encouraging.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7852218

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN： 0889-8588            Impact factor:   3.722


  2 in total

Review 1.  A risk-benefit assessment of epoetin in the management of anaemia associated with cancer.

Authors:  Y Beguin
Journal:  Drug Saf       Date:  1998-10       Impact factor: 5.606

2.  The efficacy of recombinant human erythropoietin in treatment chemotherapy induced anemia in children diagnosed with a solid cancer.

Authors:  Aa Hiradfar; M Banihosseinian
Journal:  Iran J Ped Hematol Oncol       Date:  2014-12-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.